| Ident. | Authors (with country if any) | Title |
|---|
| 001303 |
C. Twelves [Royaume-Uni] ; W. Scheithauer [Autriche] ; J. Mckendrick [Australie] ; J.-F. Seitz [France] ; G. Van Hazel [Australie] ; A. Wong [Canada] ; E. Diaz-Rubio [Espagne] ; F. Gilberg [Suisse] ; J. Cassidy [Royaume-Uni] | Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy |
| 002098 |
Andrew M. Wardley [Royaume-Uni, France, Mexique, Guatemala, Brésil, Costa Rica, Pologne, Suisse, Australie, Espagne] ; Xavier Pivot ; Flavia Morales-Vasquez ; Luis M. Zetina ; Maria De Fatima Dias Gaui ; Douglas Otero Reyes ; Jacek Jassem ; Claire Barton ; Peter Button ; Veronica Hersberger ; Antonio Anton Torres | Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer |
| 002859 |
E. Van Cutsem [Belgique] ; F. Rivera [Espagne] ; S. Berry [Canada] ; A. Kretzschmar [Allemagne] ; M. Michael [Australie] ; M. Dibartolomeo [Italie] ; M.-A. Mazier [France] ; J.-L. Canon [Belgique] ; V. Georgoulias [Grèce] ; M. Peeters [Belgique] ; J. Bridgewater ; D. Cunningham | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study |
| 002C98 |
N. Tubiana-Mathieu [France] ; P. Bougnoux [France] ; D. Becquart [Belgique] ; A. Chan [Australie] ; P.-F. Conte [Italie] ; F. Majois [Belgique] ; M. Espie [France] ; M. Morand [France] ; N. Vaissiere [France] ; G. Villanova [France] | All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial |
| 003453 |
David Cameron [Royaume-Uni] ; Michelle Casey [États-Unis] ; Michael Press [États-Unis] ; Deborah Lindquist [États-Unis] ; Tadeusz Pienkowski [Pologne] ; C. Gilles Romieu [France] ; Stephen Chan [Royaume-Uni] ; Agnieszka Jagiello-Gruszfeld [Pologne] ; Bella Kaufman [Israël] ; John Crown [Irlande (pays)] ; Arlene Chan [Australie] ; Mario Campone [France] ; Patrice Viens [France] ; Neville Davidson [Royaume-Uni] ; Veira Gorbounova [Russie] ; Johannes Isaac Raats [Afrique du Sud] ; Dimosthenis Skarlos [Grèce] ; Beth Newstat [États-Unis] ; Debasish Roychowdhury [États-Unis] ; Paolo Paoletti [États-Unis] ; Cristina Oliva [États-Unis] ; Stephen Rubin [États-Unis] ; Steven Stein [États-Unis] ; Charles E. Geyer [États-Unis] | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses |
| 006D00 |
J. Sallis [Australie] ; J. Meehan ; H. Kamperman ; M. Anderson | Chemically modified phosphocitrate and entrapment in microparticles for sustained inhibition of biomineralization |
